The Application of Long-Read Sequencing to Cancer
Cancers · 25.03.2024 · 16 (7) · 1275
DOI: 10.3390/cancers16071275 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.03.2024. Verfasst von Luca Ermini und 1 weiteren Autor:innen. Beteiligte Einrichtung: NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, L-1210 Luxembourg, Luxembourg. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is a multifaceted disease arising from numerous genomic aberrations that have been identified as a result of advancements in sequencing technologies. While next-generation sequencing (NGS), which uses short reads, has transformed cancer research and diagnostics, it is limited by read length. Third-generation sequencing (TGS), led by the Pacific Biosciences and Oxford Nanopore Technologies platforms, employs long-read sequences, which have marked a paradigm shift in cancer research. Cancer genomes often harbour complex events, and TGS, with its ability to span large genomic regions, has facilitated their characterisation, providing a better understanding of how complex rearrangements affect cancer initiation and progression. TGS has also characterised the entire transcriptome of various cancers, revealing cancer-associated isoforms that could serve as biomarkers or therapeutic targets. Furthermore, TGS has advanced cancer research by improving genome assemblies, detecting complex variants, and providing a more complete picture of transcriptomes and epigenomes. This review focuses on TGS and its growing role in cancer research. We investigate its advantages and limitations, providing a rigorous scientific analysis of its use in detecting previously hidden aberrations missed by NGS. This promising technology holds immense potential for both research and clinical applications, with far-reaching implications for cancer diagnosis and treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, L-1210 Luxembourg, Luxembourg.
- Bioscience Core Lab, King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia.
ORCID-Profile: Luca Ermini, Patrick Driguez
Zitieren
APA
Ermini, L., & Driguez, P. (2024). The Application of Long-Read Sequencing to Cancer. Cancers, 16(7), 1275. https://doi.org/10.3390/cancers16071275
Vancouver
Ermini L, Driguez P. The Application of Long-Read Sequencing to Cancer. Cancers. 2024;16(7):1275. doi:10.3390/cancers16071275
BibTeX
@article{Ermini2024,
author = {Ermini, Luca and Driguez, Patrick},
title = {The Application of Long-Read Sequencing to Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {7},
pages = {1275},
doi = {10.3390/cancers16071275}
}
EUVIMED